27 July 2017 (Thursday) - Oncologist Newsletter

Following the oncology theme the Oncologist newsletter popped into my inbox this morning. Again - interesting stuff...

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations Laura M. Spring et al.   The emergence of modern cyclin‐dependent kinase (CDK) inhibitors has changed the treatment paradigm for metastatic hormone receptor (HR)‐positive breast cancer. Palbociclib, ribociclib, and abemaciclib are highly selective reversible inhibitors of CDK4 and CDK6. Palbociclib is U.S. Food and Drug Administration (FDA)‐approved in the first‐ and second‐line settings in combination with endocrine therapy for HR‐positive metastatic breast cancer. Ribociclib is FDA‐approved in the first‐line setting. Abemaciclib has received FDA Breakthrough Therapy designation status. This review focuses on the clinical management of potential toxicities and drug interactions seen with the use of CDK4/6 inhibitors in breast cancer. In the News   NCI-COG Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers   World-Leading Cancer Researchers First in UK to Receive NovaSeq - the Latest Genome Sequencing Technology   Europe Recommends Tecentriq in Bladder Cancer, but Efficacy Doubts Persist

CME Activities   Accessibility, Availability, and Potential Benefits of Psycho-Oncology Services: The Perspective of Community-Based Physicians Providing Cancer Survivorship Care     Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging   ADVERTISEMENT

Clinical Trial Results   A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS   Lessons Learned   > Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents.   > The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested.